Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
alkaloid
topoisomerase inhibitor |
| gptkbp:ATCCode |
L01XX17
|
| gptkbp:CASNumber |
7689-03-4
|
| gptkbp:chemicalFormula |
C20H16N2O4
|
| gptkbp:discoveredBy |
gptkb:Mansukh_C._Wani
gptkb:Monroe_E._Wall |
| gptkbp:discoveredIn |
1966
|
| gptkbp:foundIn |
gptkb:Camptotheca_acuminata
|
| https://www.w3.org/2000/01/rdf-schema#label |
camptothecin
|
| gptkbp:IUPACName |
(S)-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
|
| gptkbp:mechanismOfAction |
inhibits DNA topoisomerase I
|
| gptkbp:meltingPoint |
267°C
|
| gptkbp:molecularWeight |
348.36 g/mol
|
| gptkbp:notableDerivative |
gptkb:irinotecan
gptkb:topotecan quinoline alkaloid |
| gptkbp:PubChem_CID |
gptkb:CHEMBL418
24360 CHEBI:31977 |
| gptkbp:sideEffect |
myelosuppression
gastrointestinal toxicity |
| gptkbp:solubility |
poorly soluble in water
|
| gptkbp:toxicity |
high
|
| gptkbp:UNII |
8M8G366C9E
|
| gptkbp:usedAs |
anticancer agent
|
| gptkbp:bfsParent |
gptkb:enzyme
|
| gptkbp:bfsLayer |
5
|